The House Energy and Commerce Committee yesterday released a report on the 340B Drug Pricing Program. “The 340B program is an important program that enjoys strong bipartisan support in Congress,” the report says. “The program helps reduce the prices of covered drugs for certain participating entities who, in turn, provide care for patients.” The report, which comes after two years of the committee examining the operation and oversight of the 340B program, includes a number of findings about the program, as well as 12 recommendations.

Related News Articles

Headline
Ways and Means Committee Chairman Richard Neal, D-Mass., and Energy and Commerce Committee Chairman Frank Pallone Jr., D-N.J., along with Ranking Members Kevin…
Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on seven bills aimed at improving transparency in the drug supply chain to lower…
Headline
he House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug…
Headline
The Centers for Medicare…
Blog
Drug companies are at it again. And their latest effort to divert the focus from the huge profits they pocket as drug prices rise is just as disingenuous as…
Headline
The largest U.S. pharmaceutical and biotech companies spend just 22 cents out of every dollar on research and development, according to an analysis released…